Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024)
Cogent Biosciences (COGT) recorded quarterly Long-Term Investments of $10.0 million in Q3 2024, down 62.42% quarter-over-quarter from $26.7 million in Q2 2024, and down 70.32% on a YoY basis from $33.8 million in Q4 2023.
Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024) Analysis & Trends
Cogent Biosciences' Long-Term Investments history runs 2 years deep, the most recent figure standing at $10.0 million for Q3 2024.
- In Q3 2024, Long-Term Investments fell 70.32% year-over-year to $10.0 million; the TTM figure through Sep 2024 stood at $10.0 million (down 70.32% YoY), while the FY2023 annual figure was $7.5 million, changed N/A from the prior year.
- Long-Term Investments was $10.0 million for Q3 2024 at Cogent Biosciences, down from $26.7 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $33.8 million in Q3 2023 to a low of $7.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 10.03 Mn |
| Jun 30, 2024 | 26.69 Mn |
| Dec 31, 2023 | 7.46 Mn |
| Sep 30, 2023 | 33.79 Mn |
| Jun 30, 2023 | 21.51 Mn |